Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
81
resultados
Última actualización
02/08/2026 [07:28:00]
Resultados 50 a 75 de 81
Resumen de: CN121971424A
The invention discloses a method for regulating and controlling pathological heart remodeling of an AAC model mouse by succinic acid, and belongs to the field of heart disease treatment. The method comprises the following steps: selecting 8-week-old male C57BL/6J mice, dividing the mice into a normal temperature group and a slight cold exposure group, and carrying out adaptive feeding; establishing a heart remodeling model through an AAC operation; performing 1.5% succinic acid aqueous solution and/or 1mg/mL broad-spectrum antibiotic intervention on the mouse for 4 weeks; the method comprises the following steps: collecting heart tissues, detecting heart remodeling related indexes through Masson staining, WGA staining, qPCR, Western blot and other methods, and evaluating an intervention effect. According to the invention, succinic acid is used for intervention in a slightly cold exposure environment, so that AAC model mouse pathological heart remodeling is effectively regulated and controlled, and a new method and thought are provided for research and treatment of heart remodeling diseases.
Resumen de: CN121971589A
The invention relates to the field of molecular biology and biological medicine, and particularly discloses an antithrombotic effect of Meteorin protein or gene. Experiments prove that after Meteorin protein is incubated, the platelet aggregation reaction can be remarkably inhibited, the platelet spreading area can be reduced, blood clot contraction can be delayed, and meanwhile ATP release and alpha particle release of platelets and activation of surface integrin alpha IIb beta 3 can be inhibited. In a whole thrombus experiment, the Meteorin protein can effectively inhibit the formation of arterial thrombosis. The Meteorin protein is a human endogenous protein, so that the Meteorin protein has relatively small side effects, has relatively high safety as a potential drug, and has a good industrialization prospect.
Resumen de: CN121975934A
The invention provides application of a reagent for detecting SNP sites in preparation of a product for detecting immunological rejection of organ transplantation patients. According to the present invention, the acute rejection reaction and the infection of the allogeneic organ transplantation patient can be simultaneously monitored, the genome concentration of the dd-cfDNA in the plasma can be quantified, the accurate detection of the dd-cfDNA of less than 0.5% can be achieved, the concentration calculation of the sample level can be performed on the dd-cfDNA, the sensitivity is high, and the stability is good. According to the system and the method, the physical condition of a patient subjected to allogeneic organ transplantation such as kidney transplantation, heart transplantation and lung transplantation after transplantation is regularly monitored, and a basis and a corresponding treatment scheme can be provided for dynamic monitoring and timely adjustment of the treatment scheme.
Resumen de: CN121978331A
The invention belongs to the technical field of ischemic stroke treatment, and discloses application of ULK1 possibly serving as a target spot for treating ischemic stroke. According to the invention, a photothrombotic stroke model is established, a ULK1 inhibitor SBI-0206965 (SBI), LYN1604 hydrochloride (LYN) and a ULK1 agonist are administered, and the ULK1 agonist is used for regulating the activity of ULK1 in vivo. Examples assess the outcome of sensory motor deficits, neuronal apoptosis, and microglia/macrophage activated neurological function. Immunofluorescence detection results show that ULK1 is mainly located in microglial cells in a post-ischemic infarction area of China. Upregulated ULK1 is treated by LYN, so that the infarct volume is remarkably reduced, the motor function is improved, and the increase of inflammatory microglial cells is promoted. In conclusion, the ULK1 promotes the repair of neurons and promotes the formation of 13 paths of anti-inflammatory microglial cell paths after ischemic injury.
Resumen de: CN121951022A
The invention belongs to the field of biological detection, and discloses a gene detection panel for detecting hemangioma and vascular malformation and application of the gene detection panel. The invention discloses a gene detection panel for hemangioma and vascular malformation. Comprising the gene detection panel and is used for detecting hemangioma and vascular malformation; an application of the gene detection panel in preparation of a hemangioma and vascular malformation diagnostic reagent or diagnostic kit; the gene detection panel is applied to a device for auxiliary diagnosis of etiology of hemangioma and vascular malformation patients; and the device is used for auxiliary diagnosis of pathogenesis of hemangioma and vascular malformation patients. The gene detection panel disclosed by the invention can efficiently and accurately identify gene mutation related to hemangioma and vascular deformity, can cover wide genes related to hereditary and sporadic vascular deformity, and can provide accurate information for diagnosis, treatment and prognosis evaluation of diseases.
Resumen de: CN121951024A
The invention provides a method for predicting myocarditis by using circular RNAcirc0071542 and ribosomal protein RPL13A. The method comprises the following steps: a) obtaining a biological sample of a subject; b) detecting the expression level of circACSL1 in the biological sample; c) comparing the expression level of the circACSL1 with a reference value from a healthy control; and d) when the expression level of the circACSL1 is higher than the reference value, judging that the subject has a myocarditis risk or is in a myocarditis state according to a difference value between the expression level of the circACSL1 and the reference value. The circACSL1 expression level is compared with the typical expression range of a dilated cardiomyopathy (DCM) subject to generate differential diagnosis data, and the expression difference of the marker between myocarditis and DCM can be utilized to effectively assist in clinically distinguishing the two diseases with different treatment strategies and prognosis but similar clinical manifestations.
Resumen de: CN121951028A
The invention belongs to the technical field of biology, and particularly relates to related tRF for detecting hypertrophic cardiomyopathy and a detection method and application thereof. The invention provides a marker for hypertrophic cardiomyopathy, the marker is CHAtRF, and the nucleotide sequence of the marker is as shown in SEQ ID NO: 1. The CHAtRF antisense nucleotide CHAtRF antiagomir can be used as an active ingredient in a product for treating hypertrophic cardiomyopathy. By using the CHAtRF antiagomir, the expression of CHAtRF in the heart can be inhibited, pathological myocardial hypertrophy can be remarkably inhibited, the fibrosis area can be reduced, and the effect of improving the heart function can be achieved, so that the purpose of preparing the medicine for preventing and/or treating hypertrophic cardiomyopathy by using the CHAtRF antiagomir as a novel gene therapy technology is achieved; and a new drug action target is provided for treatment of heart diseases related to hypertrophic cardiomyopathy.
Resumen de: WO2026086863A1
Disclosed are a method for assessing genomic DNA methylation status in a subject, a method for assessing risk for coronary heart disease (CHD) and a kit for detecting CHD or assessing CHD risk in a subject diagnosed or known risk for type 2 diabetes.
Resumen de: EP4733765A2
The present invention provides (1) a composition for improving pulmonary hypertension, comprising at least one substance capable of normalizing gut microbiota in a patient with pulmonary hypertension as an active ingredient; (2) a method for predicting the prognosis of a patient with pulmonary hypertension, or a method for assisting the determination of the severity of a patient with pulmonary hypertension, the method comprising detecting one or more types of bacteria selected from bacteria belonging to the family Micrococcaceae, Streptococcaceae, Pasteurellaceae, Veillonellaceae or Lactobacillaceae in gut microbiota in the patient with pulmonary hypertension; and (3) a method for assisting the diagnosis of pulmonary hypertension, the method comprising comparing the IgA level in feces of a subject to that of a healthy subject.
Resumen de: CN121926950A
The invention belongs to the technical field of medicines and disease treatment, and particularly relates to application of SEC24D in preparation of medicines for treating atherosclerosis. The amino acid sequence of the SEC24D is as shown in SEQ ID NO.1. The medicine is a preparation which takes the SEC24D as a target spot and can inhibit the expression of the SEC24D. Clinical data and basic experiments prove that the SEC24D plays an important role in inflammation, the mRNA level of whole blood cells of the SEC24D is increased to reflect the activation of the inflammation, and we find that the mRNA level and protein level of the SEC24D are increased in the polarization process of M1 macrophages, the expression of the macrophages SEC24D is reduced, the functions of the M1 macrophages can be inhibited, and inflammatory mediators can be reduced.
Resumen de: CN121931264A
The invention discloses application of a reagent for detecting abundance of intestinal flora markers in preparation of a cerebral apoplexy in-vitro diagnosis product. The method comprises the following steps: performing 16S v4 region amplicon sequencing on bacterial components in faeces of healthy people and cerebral arterial thrombosis people to obtain the abundance of bacteria, finding out flora of 18 specific genus and species as microbial markers through screening operation, and constructing a cerebral arterial thrombosis risk prediction model. Verification queue data proves that the cerebral arterial thrombosis risk prediction model is high in prediction sensitivity and good in specificity, cerebral arterial thrombosis patients and healthy individuals can be effectively distinguished in multiple samples, and the accuracy is 93% or above, so that the flora can be used as a cerebral arterial thrombosis detection marker, and the cerebral arterial thrombosis risk prediction model can be used for detecting cerebral arterial thrombosis. A reagent for detecting the abundance of the intestinal flora marker can be used for preparing a cerebral arterial thrombosis in-vitro diagnosis kit, so that a foundation is laid for early diagnosis, prevention and treatment as well as research of cerebral arterial thrombosis.
Resumen de: CN121931235A
The invention belongs to the technical field of biology, and particularly relates to related tRF for detecting myocardial ischemia injury and a detection method and application thereof. The invention provides a marker for myocardial ischemic injury, the marker is CIAtRF, and the nucleotide sequence of the CIAtRF is as shown in SEQ ID NO: 1. The expression of CIAtRF is up-regulated during myocardial injury, and CIAtRF participates in regulation and control of myocardial ischemic injury. The CIAtRF antiagomir provided by the invention can be used as an active ingredient in a product for treating myocardial ischemia reperfusion injury. By using the CIAtRF antiagomir, the expression of CIAtRF in the heart can be inhibited, the myocardial infarction area can be obviously inhibited, the fibrosis area can be reduced, and the survival rate of myocardial cells can be increased, so that myocardial ischemic injury is relieved, and the effect of improving the cardiac function is realized.
Resumen de: CN121927057A
The invention relates to application of a reagent for improving MRG15 gene expression in preparation of a medicine for treating atherosclerosis, and belongs to the technical field of biological medicine. Based on the defects that no clear molecular marker for predicting the prognosis of the atherosclerotic patient exists at present and the existing anti-atherosclerotic medicine with the main purpose of lowering lipid cannot improve the prognosis of the patient, in order to improve the treatment effect and the prognosis of the atherosclerotic patient, follow-up visit and sample dyeing are performed on the patient, so that the prognosis of the atherosclerotic patient can be A new atherosclerosis related molecule, namely MRG15, is found, correlation between improvement of MRG15 gene expression and improvement of atherosclerosis is verified, and a new prognosis target is provided for fine management of atherosclerosis patients. In order to ensure the stability of the treatment effect, a specific agonist is screened, and an excellent anti-atherosclerosis effect is achieved. Through in-vivo verification, the plaque area is reduced by 60%-70% after the small molecule medicine litamilast is applied.
Resumen de: CN121931120A
The invention relates to the technical field of nucleic acid drugs and gene therapy, in particular to a preparation method and application of endothelial cell specific modRNA. The system comprises a number 1 modRNA and a number 2 modRNA, the number 1 modRNA encodes a target protein, a 5 '-untranslated region of the number 1 modRNA comprises an L7Ae protein binding element k-turn, the number 2 modRNA encodes an L7Ae protein, a 3'-untranslated region of the number 2 modRNA comprises at least one miR126 recognition sequence, and the number 1 modRNA and the number 2 modRNA are used for being delivered into an endothelial cell; the system has no genome integration risk, the expression is regulated and controlled by miR126 in real time, and the system is suitable for vascular regeneration of targeted endothelial cells, precise gene therapy of ischemic heart disease and the like.
Resumen de: CN121933737A
The invention discloses an application of NT-IGFBP-4 and GDF-15 as biomarkers in preparation of a diagnostic reagent for clinical events related to vascular plaques. Or the NT-IGFBP-4 and/or GDF-15 are/is used as a drug target to develop a drug for treating vascular plaque. When the NT-IGFBP-4 level in a biological sample is higher than the average level of healthy individuals by 13.8% or above and the NT-IGFBP-4 level in serum reaches 119.2 ng/mL or above; or when the GDF-15 level is higher than the average level of healthy individuals by 45.2% or above and the serum GDF-15 level reaches 1221 pg/mL or above, the blood vessel plaque related clinical event is basically judged; the substance for inhibiting the expression of NT-IGFBP-4 and/or GDF-15 can be used as a candidate drug for treating vascular plaque.
Resumen de: CN121931236A
The invention discloses a systemic lupus erythematosus secondary anti-phospholipid syndrome marker and application thereof, belongs to the technical field of biomedical detection, and relates to a double-sample combined diagnosis, risk stratification and targeted therapy technology. On the basis of single cell RNA sequencing and Mendel randomization data, a skin cell-peripheral blood double-sample joint detection scheme is provided, and the diagnosis sensitivity and specificity are high; an ITGA4-MIF-PTPN22 risk layering model is constructed, and accurate risk division is achieved; a transcription factor-signal channel combined intervention preparation is developed, and the thrombus inhibition rate is high; and a rapid detection test strip is designed to meet the instant detection requirement. The method solves the problems of insufficient accuracy, single target spot and lack of layering in the prior art, and has remarkable clinical value.
Resumen de: CN121910882A
The invention provides an application of a miR-150 inhibitor in preparation of a medicine for activating an adult myocardial cell reentry cell cycle. The invention further provides a myocardial patch, the myocardial patch contains the miR-150 inhibitor, and the miR-150 inhibitor is wrapped in intracellular delivery carriers such as lipidosome, exosome, a polymer complex and inorganic nanoparticles and is further loaded on a biodegradable hydrophilic flexible polymer film or a hydrogel material. The myocardial patch provided by the invention has good biocompatibility and biodegradability, and can be degraded and absorbed; no extra adhesive is needed, the film patch can be tightly attached to the surface of the heart by means of liquid bridge force by absorbing body fluid on the surface of the heart, and the hydrogel patch can be tightly attached to the surface of the heart by means of in-situ crosslinking on the surface of the heart to form gel. The miR-150 inhibitor can be delivered into myocardial cells to activate the proliferation potential of the myocardial cells so as to promote the proliferation of the myocardial cells of damaged myocardial tissues.
Resumen de: WO2026085046A1
Disclosed herein is a method for detecting cardiomyopathy and heart failure in a subject, the method involving assaying a sample from the subject for decrease in gene or protein expression of a Obg Like ATPase 1 (OLA1) and/or the presence of a Y254C mutation in OLA1, thereby detecting cardiomyopathy and heart failure in the subject. Also disclosed is a method for treating cardiomyopathy, heart failure, myocardial infarction or heart attack, ischemic heart disease, coronary heart disease and hypertrophic cardiomyopathy in a subject, the method involving administering to the subject an expression vector comprising a nucleic acid sequence encoding wild-type Obg Like ATPase 1 (OLA1) operably linked to an expression control sequence.
Resumen de: CN121891513A
The invention discloses application of SH3RF2 in preparation of a medicine for preventing or treating cardiac hypertrophy, and relates to the technical field of new application of medicines. By constructing an in-vitro myocardial cell hypertrophy model and adopting gene knockout and overexpression technologies, the inventor finds that SH3RF2 gene knockout can significantly promote pressure load induced cardiac function deterioration and aggravate myocardial cell hypertrophy and cardiac fibrosis, and the SH3RF2 plays a role in inhibiting pathological myocardial hypertrophy. The SH3RF2 is applied to prevention and treatment of pathological cardiac hypertrophy, a new source is provided for preparation of the medicine for treating the cardiac hypertrophy, and meanwhile the medicinal value of the SH3RF2 is explored.
Resumen de: KR20260052271A
본 발명은 나트륨 누출 통로인 NALCN 및 고혈압의 상관관계 및 이를 이용한 고혈압 진단 또는 치료용 조성물에 관한 것으로, 보다 상세하게는 NALCN 억제제를 포함하는 고혈압 또는 혈관 합병증의 예방 또는 치료용 약학적 조성물, 또는 NALCN를 포함하는 고혈압 진단용 바이오마커 조성물에 관한 것이다. 본 발명에서는 혈관평활근에서 NALCN 채널을 통한 Na 유입 및 이를 통한 혈관수축 증가가 고혈압을 유발하는 것으로 확인하였으며, 알도스테론이 NALCN 채널 단백질 발현 증가를 통해 직접적으로 혈압을 증가시킴을 확인하였다. 또한, NALCN 채널이 혈관 긴장도와 혈압 조절에도 중요함을 확인하였으므로, 이를 이용하여 고혈압 진단 및 고혈압 치료 등 다양한 분야에 활용할 수 있다.
Resumen de: CN121874183A
The invention belongs to the technical field of atherosclerosis, and particularly relates to application of a Zdhhc1 gene in preparation of a product for regulating and controlling atherosclerosis, a Zdhhc1-/-mouse is successfully constructed through a CRISPR/Cas9 technology, and an ApoE-/-/Zdhhc1-/-mouse is obtained through a method of hybridization and then selfing; it is verified that knockout of the Zdhhc1 gene under the background of ApoE deletion can affect related indexes of atherosclerosis formed by high-fat feed feeding, the protein molecule Zdhhc1 affecting the atherosclerosis process is determined for the first time, and it is verified for the first time that Zdhhc1 plays an important role in occurrence and development of atherosclerosis.
Resumen de: CN121874340A
The invention discloses an application of plasma mtDNA in predicting congenital heart disease related to gestational hyperglycemia, and the application comprises the following steps: detecting the copy number of plasma mtDNA of offspring, and comparing the copy number with a preset threshold value to predict the risk that the offspring suffers from the congenital heart disease related to the gestational hyperglycemia. According to the invention, animal experiments find that plasma mtDNA level change has clear correlation with fetal congenital heart disease induced by hyperglycemia in gestation period for the first time, show good stability and consistency in the animal experiments, and can objectively reflect the heart state; therefore, the prediction method for reflecting the occurrence risk of the fetal congenital heart disease under the hyperglycemia state in the gestation period is established by taking the plasma mtDNA as the biomarker, can be applied to basic research, risk assessment and related technology development of heart dysplasia related to the hyperglycemia in the gestation period, and has relatively high practical value and popularization significance.
Resumen de: CN121852534A
The invention provides a gene detection kit for molecular diagnosis of hemangioma and vascular malformation and application. Specifically, the invention provides a gene combination for determining molecular diagnosis of hemangioma and vascular malformation, and based on NGS panel + RNAseq gene sequencing, the gene combination for molecular diagnosis of hemangioma and vascular malformation provided by the invention can be applied to all molecular diagnosis and liquid biopsy related to hemangioma and vascular malformation. The correlation between mutation sites and abundance and disease phenotypes is disclosed, so that the method has a relatively great clinical popularization and application prospect.
Resumen de: CN121852541A
The invention discloses a biomarker combination for auxiliary diagnosis of lung adenocarcinoma and risk early warning of lung adenocarcinoma complicated with ischemic stroke and application of the biomarker combination. The biomarker combination comprises an SLC25A39 gene, an NME4 gene, an LDHA gene and an SLC7A5 gene. Reagents for detecting the expression levels of the SLC25A39 gene, the NME4 gene, the LDHA gene and the SLC7A5 gene in the biomarker combination can be applied to preparation of products for auxiliary diagnosis of the lung adenocarcinoma and risk early warning of the lung adenocarcinoma complicated with ischemic stroke, and the effect of one-detection dual-energy is achieved.
Nº publicación: CN121818932A 10/04/2026
Solicitante:
WEIFANG PEOPLES HOSPITAL WEIFANG PUBLIC HEALTH CLINICAL CENTER WEIFANG OCCUPATIONAL DISEASE HOSPITAL
\u6F4D\u574A\u5E02\u4EBA\u6C11\u533B\u9662\uFF08\u6F4D\u574A\u5E02\u516C\u5171\u536B\u751F\u4E34\u5E8A\u4E2D\u5FC3\u3001\u6F4D\u574A\u5E02\u804C\u4E1A\u75C5\u533B\u9662\uFF09
Resumen de: CN121818932A
The invention discloses application of functional protein STEAP3 in preparation of drugs for preventing, diagnosing and/or treating heart failure and medical inspection products, and belongs to the technical field of medicines. The invention discloses application of targeted regulation of STEAP3 in preparation of drugs for prevention, diagnosis and/or treatment of heart failure and medical inspection products. Experiments prove that targeted regulation of the protein can significantly improve the activity of cardiac muscle cells and enhance the ability of the protein to resist stress injury, and the protein also has the following five significant activities in DOX-induced heart failure model mouse in-vivo experiments: 1) improving cardiac dysfunction; the traditional Chinese medicine composition has the effects of clearing away heat and toxic materials, reversing myocardial tissue fibrosis, improving myocardial tissue sarcoma disorder, relieving myocardial cell apoptosis and reducing myocardial cell mitochondria damage.
BOPI
Sede Electrónica
